April 25, 2018 / 12:43 PM / in 8 months

BRIEF-Abbvie's Upadacitinib Meets Primary And Key Efficacy Endpoints In Phase 2B/3 Rheumatoid Arthritis Study In Japanese Patients

April 25 (Reuters) - AbbVie Inc:

* ABBVIE’S UPADACITINIB MEETS PRIMARY AND KEY EFFICACY ENDPOINTS IN PHASE 2B/3 RHEUMATOID ARTHRITIS STUDY IN JAPANESE PATIENTS

* ABBVIE INC - SAFETY PROFILE OF UPADACITINIB WAS CONSISTENT WITH PREVIOUSLY REPORTED RESULTS, WITH NO NEW SAFETY SIGNALS DETECTED

* ABBVIE INC - SIGNIFICANTLY MORE PATIENTS RECEIVING UPADACITINIB ACHIEVED ACR50, ACR70 AND CLINICAL REMISSION AT WEEK 12 COMPARED TO PLACEBO

* ABBVIE - IN SELECT-SUNRISE, UPADACITINIB MET PRIMARY ENDPOINT OF ACR20 ACROSS ALL DOSES AT WEEK 12 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below